R. Marc Grimm3313 Octavia St., Raleigh, NC 27606

marc.grimm@gmail.com919.219.7237

2

Original artwork from a series of abstract paintings

3

Representational paintings and murals

4

Detail from nursery room mural

5

1 1 1

Pencil and Conté crayon sketches

6

Impressionist watercolor paintings

7

Original hand-made electric guitars

8

9

Graphic design, technical documents and brochure

We need your help

Call today to enroll in the MURDOCK Study

Become part of a study that aims to improve health care for our community and the world

(704) 250-5861or visit

www.murdock-study.org

Participants receive a $10 gift card for a one-time enrollment visit

IRB Protocol #11196

Convenient locations in Cabarrus Countyand Kannapolis

Are you sick?Are you healthy?

If you answered Yes to either question, the MURDOCK Study is looking for your help to improve the health care of our community and the world.

Participants will receive $10 gift cardfor a one-time enrollment visit.

Convenient locations in Cabarrus County and Kannapolis.

Call today for more information (704) 250-5861

or visit www.murdock-study.com

IRB Protocol #11196

10

See Kurtzberg page 4

May, 2011 www.dtmi.duke.edu Vol.1 Issue 1

Feinglos and Chen launch study in patients with Type I diabetes and Gastroparesis

Kurtzberg and Team move forward with Cerebral Palsy cord blood study In March, 2010, the Robert-son Foundation awarded Duke Uni-versity $10.2 million to develop a

state-of-the-art clinical and t ranslational cell therapy program (CT)2, a shared resource facil-ity advancing c e l l - b a s e d therapy re-search—partly in support of

the translational work of Drs. Joanne Kurtzberg, Gordon Worley, Ricky Goldstein, and Mohamad Mikati. As a result of this grant, Dr. Kurtzberg formed a team with these research-ers and added, Alan Song, Jessica Sun, and Kate Gustafson, to launch a study to evaluate whether a single intravenous infusion of a child's own umbilical cord stem cells will cure or at least lessen the severity of Cere-bral Palsy (CP) in children. For decades, Kurtzberg, Di-rector of Duke’s Pediatric Bone Mar-row and Transplant program and

Director of the Carolinas Cord Blood Bank, and her team have been in-vestigating the therapeutic use of umbilical cord blood stem cells, spe-cifically to treat some genetic disor-ders in children. Now, in a major effort to illustrate improvement in functional status of children with CP, Dr. Kurtzberg, Dr. Jessica Sun, and the research team are able to move forward with the first placebo-controlled, randomized, crossover clinical trial of its kind.

Joanne Kurtzberg, MD

Many Type I diabetic patients have gastrointesti-nal problems. It has been estimated that 20%-40% have gastroparesis , a condition in which muscles in the stom-ach do not function normally and are prevented from

emptying properly. The condition is of major importance and concern to dia-betic patients, interfering with diges-tion, causing nausea and vomiting, and making blood sugar levels difficult to control. Current treatments for gastro-paresis are limited, do not offer relief for many patients, and may come with a host of physical and psychological side effects, including depression, anxiety, and neuromuscular dysfunc-

tion. Device-oriented approaches do exist, such as acu-puncture and gastric stimulation, but their efficacy varies. Mark Feinglos, MD, CM, Division Chief, of Endo-crinology, Metabolism, and Nutrition at Duke and Louis Chen, MD, MBA, Endocrinology Fellow, with the support of a $20,000 DCRU Pilot Study grant and drug donation from Lilly, are studying whether the use of the erectile dysfunction (ED) drug tadalafil (Cialis®) improves gastric emptying in adult patients with diabetes and gastropare-sis. In this pilot study, 10 men and women with Type I diabetes and gastroparesis will each take a daily dose of

tadalafil for 7 days. The outcome will be measured by improvement in gastric emptying time. Small human studies have shown varying effects of a similar ED drug, on gastric emptying time. Both ED drugs may work by relax-ing certain smooth muscles in the stom-ach, thereby enabling proper flow of digested food from the stomach to the duodenum. However, other drugs in the same class as tadalafil present several drawbacks, in particular short half-lives, requiring multiple daily dosing if used to treat gastropare-sis. Daily tadalafil is a formulation that has become avail-able to consumers in recent years. Its long half-life may provide long-term relief from gastroparesis with a once-a-day pill. If the current proof-of-concept study shows re-sults, Drs. Feinglos and Chen hope to follow with a larg-er, randomized study. Dr. Feinglos is excited about the potential for this study in Type I diabetic patients with gastroparesis, and the support he has received from the DCRU. “This pilot study wouldn’t have happened without DCRU’s generous financial and staff support, as well as the forward-thinking individuals who work there; they have been unbelievably accommodating.”

Louis Chen, MD

Mark Feinglos, MD

11

Accessing the cGMP Cell and Molecular Therapeutics Facility

The Duke Translational Research Institute (DTRI), along with investment from the School of Medicine, offers a cGMP shared resource to enable the translation of novel research and clinical applications in cellular and molecular therapy—and it‘s avail-able to any investigator requiring lab space and/or specialized equipment. Facility users have access to consulting and informa-tional services from experts in diverse translational areas, including molecular thera-peutics and regulatory affairs. Researchers can also take advantage of consultation in translating current lab protocols into cGMP compliant protocols. Located in the Medical Sciences Research Building I, this facility houses state-of-the-art equipment and provides the environment and infrastructure required by the FDA to manufacture investigational cell-based and molecular therapeutic prod-ucts for pre-clinical and Phase I/II clinical studies.

Clinical Research Training Program Accepting Applications May 15

Research Career Day May 20

ESC: Heart Failure Congress May 21- 24

QuERY Day Quality Evidence Based Practice Research and You May 27

4th Annual Community Engagement National Conference August 30-31

See Facility page 3

Duke proteomics core facility receives two “next generation” mass spectrometers

The Duke University School of Medicine and NCRR have provided funding to the Duke Proteomics Core Facility for the purchase of two, state-of-the-art, ―next gen-eration‖ mass spectrometers, listing for nearly $1 million each. Designed for open, unbiased differential expression proteomics experiments, these Synapt G2 High Defi-nition Mass Spectrometers (Waters Corp.) are high-resolution exact mass instruments that not only provide a 2X increase in sample capacity for the facility, but also offer the following notable improvements in analytical capabilities for biomarker discovery: 1) Improved quantitative precision via a 4X increase in mass resolution. 2) Improved linear dynamic range of quantitation via use of a new class of ion detector; the new instruments increase this to 3.5 to 4 orders of magnitude. 3)Improved proteome cov-erage within and across samples via time-aligned parallel fragmentation experiments using unique ion-mobility optics (LC/MS/Ion-Mobility/MS). 4) Capability for analysis of proteins on the basis of their cross sectional area, allowing unique structural studies of proteins due to unique Ion Mobility optics. For example, the new instruments permit the study of changes in protein conformation as a function of ligand binding and struc-tural studies of protein multimers. See Next generation page 3

Upcoming Events

May 2011 www.dtmi.duke.edu Vol. 1, Issue 1

Medical Science Research Building (MSRB)

General Inquiries: dtriprojectoffice@mc.duke.edu Durham Office: Cynthia Chavious 919.668.8546 Angelique Kosempa 919.668.4677 Kannapolis Office: 704.250.5850 Project Office: Lynn Sutton lynn.sutton@duke.edu 919.668.8925 Consulting & Outreach : Wayne Beyer, PhD wayne.beyer@duke.edu Technologies & Resources: Virginia Burns , PhD virginia.burns@duke.edu 919.668.4647

Contact us

12

Walletproof is freeDon’t spend money on saving money, every feature of Walletproof is FREE!

It’s easy to access anywhere, anytimeIt’s as easy as scribbling down your expenses in a paper notebook.

You can start straight awayAfter registration, you can start budgeting straight away without ant fuss.

Take controlTrack your spending, and take back control of your money!

Get setup quickly!Use our handy help wizard to get

your categories setup ready to go.

Create an account.Start budgeting straight away!

Start Budgeting Today

www.walletproof.com

“...this little piggy went to

Walletproof.com.”

4.

www.walletproof.com

Track Budget Overview By Category Track your spending or earning for a specific category during a specific month

1. Click on the category in the Your Wallet sidebar to view the month’s bar graph2. To increase the range of months, click one of the links at the bottom of the graph3. To change the month, click one of the arrows on either side of the month in the sidebar 4. Click the arrows on the left to cycle backward, and the arrows on the right to cycle forward

Brochure

13

Album covers

Brochure